1-6 of 6
John Crown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B095: Sacituzumab govitecan-based drug combinations overcome platinum/PARP inhibitor resistance in ovarian cancer models

Neil T Conlon, Elena Möhrle, Luna Stockmann, John Crown
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B095.
https://doi.org/10.1158/1535-7163.TARG-23-B095
Published: 01 December 2023
View article titled, Abstract B095: Sacituzumab govitecan-based drug combinations overcome platinum/PARP inhibitor resistance in ovarian cancer models
Journal Articles

Abstract A046: Pre-clinical assessment of neratinib sensitivity and biomarkers of response

Neil T Conlon, Jeffrey J Kooijman, Guido JR Zaman, Irmina Diala, Alshad Lalani, John Crown, Denis M Collins
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A046.
https://doi.org/10.1158/1535-7163.TARG-19-A046
Published: 01 December 2019
View article titled, Abstract A046: Pre-clinical assessment of neratinib sensitivity and biomarkers of response
Journal Articles

Abstract B25: PI3K targeted inhibition in NSCLC: An in vitro evaluation and correlation of mutation status to activated PI3K pathway signaling in NSCLC patients

Susan Heavey, Sinead Toomey, Aoife Carr, Sinead Cuffe, Stephen Finn, Bryan Hennessy, John Crown, Martin Barr, Kenneth O'Byrne, Kathy Gately
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (7_Supplement): B25.
https://doi.org/10.1158/1538-8514.PI3K14-B25
Published: 06 July 2015
View article titled, Abstract B25: PI3K targeted inhibition in NSCLC: An in vitro evaluation and correlation of mutation status to activated PI3K pathway signaling in NSCLC patients
Journal Articles

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

Neil A. O'Brien, Brigid C. Browne, Lucy Chow, Yuhua Wang, Charles Ginther, Jane Arboleda, Michael J. Duffy, John Crown, Norma O'Donovan, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1489–1502.
https://doi.org/10.1158/1535-7163.MCT-09-1171
Published: 09 June 2010
View article titled, Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Open the PDF for Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib in another window
Includes: Supplementary data
Journal Articles

Insulin-like growth factor I receptor (IGF-IR) inhibition enhances response to trastuzumab in HER2-overexpressing breast cancer cells

Brigid Browne, John Crown, Natarajan Venkatesan, Mark Pegram, Martin Clynes, Michael Duffy, Dennis Slamon, Norma O'Donovan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C78.
Published: 01 November 2007
View article titled, Insulin-like growth factor I receptor (IGF-IR) inhibition enhances response to trastuzumab in HER2-overexpressing breast cancer cells
Journal Articles

Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

Virginie Durbecq, Marianne Paesmans, Fatima Cardoso, Christine Desmedt, Angelo Di Leo, Stephen Chan, Kay Friedrichs, Tamas Pinter, Simon Van Belle, Elizabeth Murray, István Bodrogi, Euan Walpole, Bernard Lesperance, Stefan Korec, John Crown, Peter Simmonds, Thimothy J. Perren, Jean-Yves Leroy, Ghizlane Rouas, Christos Sotiriou, Martine Piccart, Denis Larsimont
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (10): 1207–1214.
https://doi.org/10.1158/1535-7163.1207.3.10
Published: 14 October 2004
View article titled, Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
Open the PDF for Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel in another window